288 related articles for article (PubMed ID: 31982173)
1. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
[TBL] [Abstract][Full Text] [Related]
2. Linear bullous lichen planus associated with nivolumab.
Biolo G; Caroppo F; Salmaso R; Alaibac M
Clin Exp Dermatol; 2019 Jan; 44(1):67-68. PubMed ID: 29920744
[No Abstract] [Full Text] [Related]
3. Nivolumab-induced lichen planus.
Yilmaz M; Mese SG; Celik U
J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
[TBL] [Abstract][Full Text] [Related]
4. Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.
Shah RR; Bhate C; Hernandez A; Ho CH
Dermatol Ther; 2022 May; 35(5):e15432. PubMed ID: 35266258
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced lichen planus pemphigoides.
Strickley JD; Vence LM; Burton SK; Callen JP
Cutis; 2019 Apr; 103(4):224-226. PubMed ID: 31116807
[TBL] [Abstract][Full Text] [Related]
6. A case of severe nivolumab-induced lichen planus pemphigoides in a child with metastatic spitzoid melanoma.
Mueller KA; Cordisco MR; Scott GA; Plovanich ME
Pediatr Dermatol; 2023 Jan; 40(1):154-156. PubMed ID: 35882548
[TBL] [Abstract][Full Text] [Related]
7. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
8. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
[TBL] [Abstract][Full Text] [Related]
9. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
Sato Y; Fujimura T; Mizuashi M; Aiba S
J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
[No Abstract] [Full Text] [Related]
10. Multiple erosive lichen planus preceded by solitary lichen planus after combination therapy with nivolumab and radiation.
Komori T; Honda T; Irie H; Otsuka A; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e382-e384. PubMed ID: 28295693
[No Abstract] [Full Text] [Related]
11. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
Coscarart A; Martel J; Lee MP; Wang AR
J Cutan Pathol; 2020 Mar; 47(3):275-279. PubMed ID: 31589773
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-related lichen planus of the lip in a patient with head and neck cancer.
Economopoulou P; Nicolatou-Galitis O; Kotsantis I; Psyrri A
Oral Oncol; 2020 May; 104():104623. PubMed ID: 32144002
[TBL] [Abstract][Full Text] [Related]
14. [Coexistence of lichen planus and bullous pemphigoid (an immunofluorescence study of a "lichen pemphigoides") (author's transl)].
Saurat JH; Guinepain MT; Didierjean L; Sohier J; Puissant A
Ann Dermatol Venereol; 1977 May; 104(5):368-74. PubMed ID: 72516
[TBL] [Abstract][Full Text] [Related]
15. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
16. Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy.
Miyagawa F; Nakajima A; Ohyama SI; Aoki Y; Nishikawa M; Nakamura Y; Hashimoto T; Asada H
Acta Derm Venereol; 2019 Jun; 99(7):687-688. PubMed ID: 30938822
[No Abstract] [Full Text] [Related]
17. Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy.
Matsumoto Y; Kadono T; Matsuoka M; Kawakami T; Furuya N; Doi M; Hoshikawa M; Soma Y
J Dermatol; 2018 Feb; 45(2):e33-e34. PubMed ID: 28984022
[No Abstract] [Full Text] [Related]
18. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.
Reschke R; Mockenhaupt M; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2019 Sep; 17(9):942-948. PubMed ID: 31210413
[No Abstract] [Full Text] [Related]
19. Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade.
Wat M; Mollanazar NK; Ellebrecht CT; Forrestel A; Elenitsas R; Chu EY
J Cutan Pathol; 2022 Nov; 49(11):978-987. PubMed ID: 36054729
[TBL] [Abstract][Full Text] [Related]
20. Umbilical lichen planus induced by nivolumab.
Martos-Cabrera L; Lladó I; Fernández-Rico P; Butrón-Bris B; Rodríguez-Jiménez P
An Bras Dermatol; 2023; 98(5):712-714. PubMed ID: 37164791
[No Abstract] [Full Text] [Related]
[Next] [New Search]